Hydrochlorothiazide (HCTZ) use is associated with increased risk of Basal Cell and Squamous Cell Carcinoma

A recent study published in the Journal of the American Academy of Dermatology has shown that taking hydrochlorothiazide (HCTZ) is associated with an increased risk of basal cell carcinoma and an even higher risk of squamous cell carcinoma. The risk was dose dependent (the higher the cumulative dose, the higher the risk).

An increased risk was not seen with other anti-hypertensive agents or diuretics.


Black Salve not recommended for Skin Cancer

According to a study published in the Journal of the American Academy of Dermatology, 74% of persons using black salve were not aware of the possible side effects of the remedy, including infection, scarring, and disfigurement. Black salve can destroy the top layer of skin, but most cancers lie beneath this layer and continue to grow.

CONCLUSION: Black Salve is NOT recommended for the treatment of nearly all skin cancers, and should not be used unless under the supervision of a board-certified Dermatologist.

Melanoma drug Vemurafenib may increase risk of squamous cell carcinoma

According to a study published in the New England Journal of Medicine, Vemurafenib (Zelboraf) speeds the growth of squamous cell carcinoma. HealthDay explained that “roughly one-quarter of patients who take the medication develop a troublesome side effect: secondary skin cancers called squamous cell carcinomas.”